Cancer clinical trials in the region Bourgogne-Franche-Comté

152 currently recruiting clinical trials
Region Bourgogne-Franche-Comté

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Negative (< 1%) None Systemic Treatment-Naive
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Besançon (Besançon)
Amgen
Phase 3 Stomach and esophageal cancer
#NCT06346392
Stomach Oesogastric junction Esophagus Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 1 2 3 or more Chemotherapy
HER2 Systemic Treatment-Naive
Centre Hospitalier Universitaire de Besançon (Besançon)
AstraZeneca
Phase 3 Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive
Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Besançon (Besançon)
Daiichi Sankyo